AC Immune reports 12-month interim data from ABATE Phase 1b/2 trial of ACI-24 in prodromal Alzheimer’s disease
PUBT · 4d ago
Share
Listen to the news
- AC Immune released interim 12-month results from the Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer’s disease.
- The first three patient cohorts showed ACI-24 was generally safe and well tolerated, with no ARIA-E signals reported.
- Antibody responses were observed across all tested dose levels, supporting a dose-response effect.
- A fourth cohort has started to test an added adjuvant intended to strengthen immune responses for potentially greater plaque removal.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300700OMX_____CNEWS_EN_GNW1001210321_en) on June 30, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved